Decreased serum arylesterase activity in autism spectrum disorders

[1]  C. Lintas,et al.  Association of autism with polyomavirus infection in postmortem brains , 2010, Journal of Neurovirology.

[2]  B. Nemeș,et al.  Paraoxonase 1 activities and polymorphisms in autism spectrum disorders , 2008, Journal of cellular and molecular medicine.

[3]  S. Puglisi‐Allegra,et al.  Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1 , 2010, Molecular Psychiatry.

[4]  K. Mirnics,et al.  Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression , 2009, Molecular Psychiatry.

[5]  J. Joven,et al.  Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. , 2009, Mini reviews in medicinal chemistry.

[6]  A. Hubbard,et al.  Developmental Changes in PON1 Enzyme Activity in Young Children and Effects of PON1 Polymorphisms , 2009, Environmental health perspectives.

[7]  N. Holland,et al.  Validation of PON1 enzyme activity assays for longitudinal studies. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[8]  J. Joven,et al.  Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease , 2009, BMC gastroenterology.

[9]  R. Banerjee,et al.  One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders , 2008, Journal of cellular and molecular medicine.

[10]  S. Chia,et al.  Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populations--a short review. , 2008, Industrial health.

[11]  J. Joven,et al.  Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. , 2008, Free radical biology & medicine.

[12]  Károly Mirnics,et al.  Immune transcriptome alterations in the temporal cortex of subjects with autism , 2008, Neurobiology of Disease.

[13]  G. Paragh,et al.  Book - The Paraoxonases: Their role in disease development and xenobiotic metabolism , 2008 .

[14]  I. Hațieganu,et al.  One Carbon Metabolism Disturbances and the C667T MTHFR Gene Polymorphism in Children with Autism Spectrum Disorders. , 2008 .

[15]  B. Coll,et al.  Paraoxonase-1 in Chronic Liver Diseases, Neurological Diseases and HIV Infection , 2008 .

[16]  T. Bourgeron,et al.  Abnormal melatonin synthesis in autism spectrum disorders , 2008, Molecular Psychiatry.

[17]  B. Coll,et al.  Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. , 2007, Atherosclerosis.

[18]  Craig Wolff,et al.  Maternal Residence Near Agricultural Pesticide Applications and Autism Spectrum Disorders among Children in the California Central Valley , 2007, Environmental health perspectives.

[19]  Mao Sheng Yang,et al.  A review of gene linkage, association and expression studies in autism and an assessment of convergent evidence , 2007, International Journal of Developmental Neuroscience.

[20]  S. Puglisi‐Allegra,et al.  Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1 , 2007, BMC Medical Genetics.

[21]  Stepan Melnyk,et al.  Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[22]  A. Chauhan,et al.  Oxidative stress in autism. , 2006, Pathophysiology : the official journal of the International Society for Pathophysiology.

[23]  T. Bourgeron,et al.  Searching for ways out of the autism maze: genetic, epigenetic and environmental clues , 2006, Trends in Neurosciences.

[24]  P. Ashwood,et al.  The immune response in autism: a new frontier for autism research , 2006, Journal of leukocyte biology.

[25]  B. Nemeș,et al.  High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. , 2006, Life sciences.

[26]  B. Coll,et al.  Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[27]  F. Macciardi,et al.  Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene–environment interactions , 2005, Molecular Psychiatry.

[28]  R. Sunahara,et al.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M , 2005, Journal of Lipid Research.

[29]  C. Gillberg,et al.  Autism associated with conditions characterized by developmental errors in early embryogenesis: a mini review , 2005, International Journal of Developmental Neuroscience.

[30]  T. Kemper,et al.  Neuroanatomic observations of the brain in autism: a review and future directions , 2005, International Journal of Developmental Neuroscience.

[31]  M. Rutter,et al.  Incidence of autism spectrum disorders: Changes over time and their meaning * , 2005 .

[32]  A. Zimmerman,et al.  Neuroglial activation and neuroinflammation in the brain of patients with autism , 2005, Annals of neurology.

[33]  R. Barouki,et al.  Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans , 2005, Thrombosis and Haemostasis.

[34]  R. Barouki,et al.  Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia , 2004, Thrombosis and Haemostasis.

[35]  Alessandro Quattrone,et al.  Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism , 2004, Biological Psychiatry.

[36]  Xin Xu,et al.  Family‐based tests for associating haplotypes with general phenotype data: Application to asthma genetics , 2004, Genetic epidemiology.

[37]  D. Sok,et al.  Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. , 2003, The Biochemical journal.

[38]  J. Joven,et al.  Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. , 2003, Clinical chemistry.

[39]  A. Tward,et al.  Expression of human paraoxonase (PON1) during development. , 2003, Pharmacogenetics.

[40]  Jia Chen,et al.  Increased influence of genetic variation on PON1 activity in neonates. , 2003, Environmental health perspectives.

[41]  A. Kuksis,et al.  Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. , 2003, Cardiovascular research.

[42]  Walter C Willett,et al.  Optimal diets for prevention of coronary heart disease. , 2002, JAMA.

[43]  M. Fishbein,et al.  Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide , 2002, Circulation.

[44]  G. Schellenberg,et al.  Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[45]  A. Tward,et al.  Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.

[46]  S. Spence,et al.  The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. , 2001, American journal of human genetics.

[47]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[48]  D. Nayak,et al.  High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection , 2001, Circulation.

[49]  D. Barr,et al.  Measurement of organophosphate metabolites in postpartum meconium as a potential biomarker of prenatal exposure: a validation study. , 2001, Environmental health perspectives.

[50]  A. Tward,et al.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. , 2000, Pharmacogenetics.

[51]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[52]  D. Shih,et al.  Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). , 2000, Neurotoxicology.

[53]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[54]  B. La Du,et al.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[55]  T. Standiford,et al.  On the physiological role(s) of the paraoxonases. , 1999, Chemico-biological interactions.

[56]  D. Shih,et al.  The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. , 1999, Chemico-biological interactions.

[57]  R. Walker,et al.  Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[58]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[59]  S Arndt,et al.  Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. , 1997, The American journal of psychiatry.

[60]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[61]  D. Curtis,et al.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci , 1995, Annals of human genetics.

[62]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[63]  R. Abramson,et al.  Elevated blood serotonin in autistic probands and their first-degree relatives , 1989, Journal of autism and developmental disorders.

[64]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[65]  A. Motulsky,et al.  Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. , 1983, American journal of human genetics.

[66]  D. Evans,et al.  Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.

[67]  D. Winzor,et al.  Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. , 1973, The Biochemical journal.

[68]  K. Augustinsson,et al.  AGE VARIATION IN PLASMA ARYLESTERASE ACTIVITY IN CHILDREN. , 1963, Clinica chimica acta; international journal of clinical chemistry.